HeartScore.Co and CerebraCell Announce Joint Venture for Tele-Stroke Management and Recovery
Innovative Protocol Focuses Not Only on Management of Time = Brain but Full Functional Recovery
Press Release – August 3rd, 2016 – Santa Monica, CA and Salt Lake City, UT – HeartScore.co and CerebraCell today announced the launch of a new initiative to utilize genomics, high fidelity imaging plus monitoring, point of care diagnostics and bioelectric + stem cell based stroke recovery technologies to attempt to improve cerebral stroke management results.
Some of the components the HeartScore.co & CerebraCell TeleStroke Management & Recovery Program will include:
“The HeartScore.co and CerebraCell tele-stroke management and recovery program incorporates a convergence of the best practices in remote monitoring, precision medicine, point of care diagnostics, stem cell, yoga therapy and bioelectric treatment for stroke management and recovery. We have high expectations for an upcoming clinical trial.” states Dr. Santosh Kesari, CerebraCell Chief Advisor Cerebrovascular Science, and Director of Neuro-Oncology at Providence Saint John’s Health Center and chair of the Department of Translational Neuro-oncology and Neurotherapeutics at John Wayne Cancer Institute.
Kaiser Permanente of California announced earlier this week the success of their internal independent (no association with HeartScore.co) tele-stroke management program which included just a few of the components of the intended HeartScore.co + CerebraCell protocol design – see press coverage here http://www.fiercebiotech.com/medical-devices/kaiser-permanente-s-telestroke-program-pays-off
HeartScore.co and CerebraCell intend to complete implementation of animal safety studies with intention to launch a human clinical trial of this combination sometime in 2017.
Stroke is the third leading cause of death in developed countries. Each year, stroke occurs in over 15 million patients worldwide, leaving many with disabilities and unable to resume their previous quality of life or to maintain gainful employment. This makes the social and economic impact of stroke one of the most devastating.
The HeartScore TeleStroke Program could be an important component of a patients’ stroke care by helping Physicians to rapidly evaluate and treat stroke patients. There is an FDA-approved medicine (tissue plasminogen activator, tPA) that in some patients can help reverse the disability of stroke if given within the first 3 hours of stroke. When it comes to the assessment and treatment of stroke patients,”time is brain”. The faster a patient receives proper treatment for stroke, the better the chances for recovery.
By establishing a HeartScore.co Tele-Stroke Program using video conferencing and image sharing technology, stroke specialists from participating centers can examine patients from remotes locations over distances to help diagnose the patient’s condition and recommend a precision personalized course of care.
80% of strokes are ischemic strokes – an affliction in which a blood clot, formed in another part of the body, travels to a smaller blood vessel in the brain and becomes lodged, blocking the blood flow to that area.
Unfortunately, some hospitals lack the resources to make this determination and cannot physically transfer the patient quickly enough to enable them to receive brain saving therapy in a timely manner. This is where the HeartScore Tele-Stroke Program goes to work. Subscribing hospitals can receive acute stroke care for patients without physically transferring the patient for an exam. One form of treatment is to administer Tissue Plasminogen Activator (tPA), a clot busting drug that can greatly reduce the disability resulting from a stroke. tPA must be administered within 4.5 hours of symptom onset. Another, expected soon to enter clinical trials as part of this protocol, is the CerebraCell combination bioelectric regeneration stimulator (controls release of 10 regenerative proteins including a stem cell homing signal) + stem cell composition micro infusion pump (Investigational Use Only). This CerebraCell bioelectric + stem cell composition therapy is administered via a brain cap with micro elecro acupuncture needles that takes only a few minutes to apply to a patient’s head and is easily administered by care providers under remote physician supervision. See demonstration video – https://vimeo.com/175899331
A physician can examine someone very interactively with the help of a care provider on the other end and can make a determination of the stroke severity and the type of stroke. This is done by visual examination of the patient remotely and by the brain images and filtered analyzed EEG data as well as results from the point of care diagnostic tests including genomic profiling with that information sent to the physician by smart phone. The goal is to make it as close as possible to match as if the patient was right there in a stroke center of excellence physicians office.
HeartScore.co and CerebraCell are incubating within Leonhardt Ventures affiliated incubators at the University of Northern California Science & Technology Center in Rohnert Park, CA, Cal-X Stars Business Accelerator, Inc. in Santa Monica, CA and Leonhardt’s Launchpads Utah in Salt Lake City, UT.
HeartScore.co founded in 2014 focuses on heart failure and stroke management based on genomics, blood tests, imaging and high fidelity monitoring. – www.heartscore.co/heart-failure-management/
CerebraCell founded in 2015 is focused on brain regeneration utilizing patented bioelectric signals that home stem cells to the brain and cause new blood vessels to grow combined when necessary with a micro stem cell infusion pump that delivers Cerebracell’s proprietary fifteen component regeneration and angiogenic compositions – www.leonhardtventures.com/cerebracell/
About Leonhardt Ventures:
Leonhardt Ventures formed in 1982 is focused on accelerating regenerative medtech and regenerative economy innovations – www.leonhardtventures.com working via incubators/accelerators in Santa Monica, CA, Rohnert Park, CA and Salt Lake City, Utah.
About Dr. Santosh Kesari:
Santosh Kesari, M.D., Ph.D., is a board-certified neurologist and neuro-oncologist. He serves as director of neuro-oncology at Providence Saint John’s Health Center and chair of the Department of Translational Neuro-oncology and Neurotherapeutics at John Wayne Cancer Institute.
A physician and scientist, Dr. Kesari specializes in personalized medicine for patients with malignant brain tumors. His experience in precision therapeutic strategies targets brain tumors at the molecular level to eliminate the disease. Dr. Kesari’s research efforts have focused on cancer stem cells, their role in the formation of brain tumors and their resistance to treatment. His goal is to advance neurological medicine by developing targeted drugs to eradicate brain tumors. He has more than 200 publications, including original articles, reviews, editorials, books and clinical communications. Dr. Kesari has received countless awards and recognition throughout his medical career, and he was named one of America’s Top Doctors by Castle Connolly. Dr. Kersari joined CerebraCell as an advisor in 2015.